These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34529358)

  • 1. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
    Huang RS; Lai MC; Lin S
    Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A robust platform for expansion and genome editing of primary human natural killer cells.
    Huang RS; Lai MC; Shih HA; Lin S
    J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33433623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for genomic editing in human resting primary NK cells and NK-92 cells via CRISPR-Cas9 ribonucleoproteins.
    Verhezen T; Lau HW; Van Audenaerde J; Wouters A; Smits E; De Waele J
    STAR Protoc; 2024 Sep; 5(3):103123. PubMed ID: 38935511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
    Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient Cas9-based Genome Editing Using CRISPR Analysis Webtools in Severe Early-onset-obesity Patient-derived iPSCs.
    Patel A; Iannello G; Diaz AG; Sirabella D; Thaker V; Corneo B
    Curr Protoc; 2022 Aug; 2(8):e519. PubMed ID: 35950852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient and stable CRISPR/Cas9-mediated genome-editing of human type 2 innate lymphoid cells.
    Audouze-Chaud J; Mathews JA; Crome SQ
    Front Immunol; 2023; 14():1275413. PubMed ID: 37868976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
    Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
    Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
    Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
    Front Immunol; 2020; 11():1008. PubMed ID: 32528479
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
    Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
    Methods Mol Biol; 2020; 2121():213-239. PubMed ID: 32147798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient Multi-Allelic Genome Editing of Primary Cell Cultures via CRISPR-Cas9 Ribonucleoprotein Nucleofection.
    Hoellerbauer P; Kufeld M; Paddison PJ
    Curr Protoc Stem Cell Biol; 2020 Sep; 54(1):e126. PubMed ID: 32833346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.
    Naeimi Kararoudi M; Dolatshad H; Trikha P; Hussain SA; Elmas E; Foltz JA; Moseman JE; Thakkar A; Nakkula RJ; Lamb M; Chakravarti N; McLaughlin KJ; Lee DA
    J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samples.
    Eerkens AL; Vledder A; van Rooij N; Foijer F; Nijman HW; de Bruyn M
    Immunol Cell Biol; 2022 Apr; 100(4):285-295. PubMed ID: 35194830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
    Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
    Bexte T; Alzubi J; Reindl LM; Wendel P; Schubert R; Salzmann-Manrique E; von Metzler I; Cathomen T; Ullrich E
    Oncoimmunology; 2022; 11(1):2081415. PubMed ID: 35694192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
    Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9 Genome Editing and Rapid Selection of Cell Pools.
    Stoyko D; O T; Hernandez A; Konstantinidou P; Meng Q; Haase AD
    Curr Protoc; 2022 Dec; 2(12):e624. PubMed ID: 36546759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9 Genome Editing of Primary Human Vascular Cells In Vitro.
    Atri DS; Lee-Kim VS; Vellarikkal SK; Sias-Garcia O; Yanamandala M; Schniztler GR; Gupta RM
    Curr Protoc; 2021 Nov; 1(11):e291. PubMed ID: 34748284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 Genome Editing in the Moss Physcomitrium (Formerly Physcomitrella) patens.
    Wu SZ; Ryken SE; Bezanilla M
    Curr Protoc; 2023 Apr; 3(4):e725. PubMed ID: 37021953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
    Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.